# Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer

> **NCT07267078** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Tuvonralimab/Iparomlimab combination with GEMOX chemotherapy

## Key facts

- **NCT ID:** NCT07267078
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-25
- **Primary completion:** 2028-01-25
- **Final completion:** 2028-05-25
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07267078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07267078, "Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07267078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*